Bharat Biotech's nasal covid booster dose gets approval for trials1 min read . Updated: 05 Jan 2022, 10:16 AM IST
- Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin)
DCGI's Subject Expert Committee (SEC) has granted 'in principle' approval to Bharat Biotech for the conduct of 'Phase III superiority study and Phase III booster dose study' for its intranasal COVID vaccine and has asked it to submit protocols for approval, according to news agency ANI.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more